Table 2.
Characteristics of disease relapse prior to focal salvage HDR brachytherapy.
| Characteristic | Number (%) |
|---|---|
| Type of failure of primary treatment | |
| Biochemical | 39 (91%) |
| Histological | 4 (9%) |
| Median PSA at relapse (range) | 3.1 (1.1–7.5) |
| Type of biopsy | |
| Full template | 3 (7%) |
| Four quadrants | 24 (56%) |
| Four quadrants + targeted | 13 (30%) |
| Targeted only | 2 (5%) |
| TRUS | 1 (2%) |
| Re-biopsy ISUP grade | |
| 1 | 2 (5%) |
| 2 | 13 (30%) |
| 3 | 11 (26%) |
| 4 | 6 (14%) |
| 5 | 7 (16%) |
| Ungradable | 4 (9%) |
| ISUP upgraded at re-biopsy | |
| Yes | 27 (63%) |
| No | 12 (28%) |
| Ungradable | 4 (9%) |
| Imaging prior to salvage HDR brachytherapy | |
| MRI alone | 9 (21%) |
| PET-CT alone | 8 (19%) |
| Both MRI and PET-CT | 26 (60%) |
| Dose/fractionation of focal salvage HDR brachytherapy | 19 Gy in one fraction (100%) |
| ADT with focal salvage HDR brachytherapy | |
| None | 11 (26%) |
| 6 months | 19 (44%) |
| 2–3 years | 9 (21%) |
| Castrate resistant- continued hormone therapy | 4 (9%) |